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The peroxisome proliferator-activated receptor- (PPAR,
NR1C3) in complex with the retinoid X receptor (RXR) plays
a central role in white adipose tissue (WAT) differentiation
and function, regulating the expression of keyWAT proteins.
In this report we show that poly(ADP-ribose) polymerase-2
(PARP-2), also known as an enzyme participating in the sur-
veillance of the genome integrity, is a member of the PPAR/
RXR transcription machinery. PARP-2/ mice accumulate
less WAT, characterized by smaller adipocytes. In the WAT
of PARP-2/ mice the expression of a number of PPAR
target genes is reduced despite the fact that PPAR1 and -2
are expressed at normal levels. Consistent with this, PARP-
2/mouse embryonic fibroblasts fail to differentiate to adi-
pocytes. In transient transfection assays, PARP-2 small inter-
ference RNA decreases basal activity and ligand-dependent
activation of PPAR, whereas PARP-2 overexpression
enhances the basal activity of PPAR, although it does not
change the maximal ligand-dependent activation. In addi-
tion, we show a DNA-dependent interaction of PARP-2 and
PPAR/RXR heterodimer by chromatin immunoprecipita-
tion. In combination, our results suggest that PARP-2 is a
novel cofactor of PPAR activity.
Adipose tissue is composed of adipocytes that store energy in
the form of triglycerides. Excessive accumulation of white adi-
pose tissue (WAT)2 leads to obesity, whereas its absence leads
to lipodystrophic syndromes. The peroxisome proliferator-
activated receptor- (PPAR, NR1C3) is the main protein
orchestrating the differentiation and function of WAT, as
evidenced by the combination of in vitro studies, the analysis
of mouse models, and the characterization of patients with
mutations in the human PPAR gene (1, 2). PPAR acts as
heterodimer with the retinoid X receptor (RXR) (3). The
PPAR/RXR receptor dimer is involved in the transcrip-
tional control of energy, lipid, and glucose homeostasis (4,
5). The actions of PPAR are mediated by two protein iso-
forms, the widely expressed PPAR1 and adipose tissue-re-
stricted PPAR2, both produced from a single gene by alter-
native splicing and differing only by an additional 28 amino
acids in the N terminus of PPAR2 (3, 6).
PPAR is activated by binding of small lipophilic ligands,
mainly fatty acids, derived from nutrition or metabolic path-
ways, or synthetic agonists, like the anti-diabetic thiazoli-
denediones (2, 7, 8). Docking of these ligands in the ligand
binding pocket alters the conformation of PPAR, resulting
in transcriptional activation subsequent to the release of
corepressors and the recruitment of coactivators. Many
corepressors and coactivators have been described such as the
nuclear receptor corepressor and the steroid receptor coactiva-
tors, also known as p160 proteins (9–11). These corepressors
and coactivators determine transcriptional activity by altering
chromatin structure via enzyme such as histone deacetylases
and histone acetyltransferases (CREB-binding protein/p300).
Othermechanisms includeDNAmethylation, ATP-dependent
remodeling, protein phosphorylation, sumoylation, ubiquitiny-
lation, and poly(ADP-ribosyl)ation.
* Thisworkwas supportedby INSERM,Universite´ Louis Pasteur, the European
Union (Grant LSHM-CT-2004-512013), National Institutes of Health Grant
DK 067320, Federation of European Biochemical Societies (long term fel-
lowship), CNRS, Association pour la Recherche contre le Cancer, Electricite´
de France, Ligue contre le Cancer, Commissariat a` l’Energie Atomique and
Agence Nationale pour la Recherche, Ministe`re des Affaires Etrange`res,
Ambassade de la France en Hongrie, and a Bolyai Fellowship of the Hun-
garian Academy of Sciences (to P. B.). The authors declare no conflict of
interest. The costs of publication of this articlewere defrayed in part by the
payment of page charges. This article must therefore be hereby marked
“advertisement” in accordance with 18 U.S.C. Section 1734 solely to indi-
cate this fact.
This work is dedicated to the memory of Josiane Me´nissier-de Murcia, who
passed away (July 15, 2007).
1 To whom correspondence should be addressed. Tel.: 36-52-412-345; Fax:
36-52-412-566; E-mail: baip@dote.hu.
2 The abbreviations used are: WAT, white adipose tissue; PPAR, peroxisome
proliferator-activated receptor; PARP-1 and -2, poly(ADP-ribose) polymer-
ase-1 and -2; TTF1, thyroid transcription factor-1; WT, wild type; RT-qPCR,
reverse transcription-coupled quantitative PCR; aP2, adipocyte fatty acid-
bindingprotein 2; ER, estrogen receptor; K19, keratin-19; ChIP, chroma-
tin immunoprecipitation; RXR, retinoidX receptor;HEK293, humanembry-
onic kidney 293; TNF, tumor necrosis factor ; CREB, cAMP-response
element-binding protein; DMEM, Dulbecco’s modified Eagle’s medium;
MEF, mouse embryonic fibroblast; siRNA, small interference RNA; BES,
2[bis(2-hydroxyethyl)amino]ethanesulfonic acid.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 282, NO. 52, pp. 37738–37746, December 28, 2007
© 2007 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
37738 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 282•NUMBER 52•DECEMBER 28, 2007
 by on April 17, 2008 
w
w
w
.jbc.org
D
ow
nloaded from
 
Poly(ADP-ribose) polymerase-2 (PARP-2) was described by
Ame et al. (12) in 1999 as a 66.2-kDa nuclear protein with poly-
(ADP-ribosyl)ating activity. Through its DNA-binding domain
in the N terminus (amino acids 1–62), PARP-2 can bind to
DNase I-treated DNA and to aberrant DNA forms, and its sub-
sequent activation results in poly(ADP-ribose) polymer forma-
tion (12). According to the general scheme of PARP activation,
the active enzyme catalyzes the polymerization of poly(ADP-
ribose) polymer onto different acceptor proteins and itself
using NAD as a substrate (13). PARP-2 shares a similar cata-
lytic domain (amino acid 202–593) as poly(ADP-ribose) poly-
merase-1 (PARP-1) (14), the founding member of the PARP
family, though PARP-2 has a smaller reaction velocity com-
pared with PARP-1 (12).
PARP-2 has multiple in vivo functions comprising DNA
surveillance and DNA repair processes (reviewed in Ref. 15),
spermatogenesis (16, 17), inflammation, and oxidative injury
(18–20). Most of these functions are accomplished through
protein-protein interactions. In PARP-2, the interaction plat-
forms can be mapped to the DNA-binding domain and to the
domain E (amino acids 63–202) (21–25). A role for PARP-2 in
the regulation of transcription has already been described. In
lung epithelial cells PARP-2 interacts with thyroid transcrip-
tion factor-1 (TTF1). TTF1 is a homeodomain-containing tran-
scription factor of the Nkx-2 family. In these cells, PARP-2 reg-
ulates the expression of the surfactant protein-B by affecting
TTF1 activity (25). In this study we show that PARP-2 affects
the transcriptional activity of PPAR both in vitro and in vivo.
EXPERIMENTAL PROCEDURES
Materials—All chemicals were from Sigma-Aldrich unless
stated otherwise.
Animals—PARP-2/mice and their wild-type (WT) litter-
mates (26) coming from heterozygous crossings were used.
Mice were housed separately, had ad libitum access to water
and chow, and were kept under a 12-h dark-light cycle. The
animals were killed at the age of 7 months by cervical disloca-
tion after 4 h of fasting, and tissues were collected.
Cell Culture—3T3-L1 cells were maintained in DMEM
(Invitrogen), 10%newborn calf serum (Invitrogen), Gentamicin
(Invitrogen), and HEK, and mouse embryonic fibroblasts
(MEFs) were maintained in DMEM, 10% fetal calf serum
(Adgenix, Voisins le Bretonneux, France), and Gentamicin
(Invitrogen). The 3T3-L1 cells were maintained subconfluent.
MEF Preparation and Differentiation—MEFs were prepared
from embryos as described elsewhere (26). For the differentia-
tion studies 4  105 MEFs were seeded in 12-well plates and
maintained in DMEM, 10% fetal calf serum. The medium was
changed every 2 days until confluence. The cells were main-
tained at confluency for 2 days. Cells were then differentiated in
DMEM, 10% newborn calf serum, 5 M troglitazone, 5 M
dexamethasone, 500M isobutylmethylxanthine, and 10g/ml
insulin (later defined as differentiation mix), while the control
cells receivedDMEM, 10% fetal calf serum, andMe2SO as vehi-
cle. The medium with the differentiation mix was replaced
every 2 days, and the cells were differentiated for 8 days. Con-
trol cells after confluency were cultured in DMEM plus 10%
fetal calf serum containing only vehicle (Me2SO, 0.21%).
DNAConstructs—To create an siRNA-expressing construct,
double stranded oligonucleotides were cloned into the pSuper
vector (for sequences see Table 1) (27). The oligonucleotides
siPARP-2sense and siPARP-2antisense (containing the siRNA
sequence), aswell as the control scrPARP-2sense and scrPARP-
2antisense (scrambled version of the siRNA sequence), respec-
tively, were annealed in annealing buffer (150 mM NaCl, 1 mM
EDTA, 50 mM Hepes, pH. 8.0). The resulting duplexes carried
BglII andHindIII sites and were cloned into pSuper using these
sites resulting in pSuper-siPARP-2 (oligonucleotides siPARP-
2sense plus siPARP-2antisense) and pSuper-scrPARP-2 (oligo-
nucleotides scrPARP-2sense plus scrPARP-2antisense). An
EcoRV/SmaI fragment encoding mouse PARP-2 was isolated
from pBC-mPARP-2 (23) and inserted into the SnaBI site of
pBABEpuro (Addgene, Cambridge, MA), giving the pBABE-
mPARP-2 vector. All other constructs pGL3-(Jwt)3TKluc
reporter construct (28), pSG-PPAR2 (3), pSG5-PPAR (29),
pSG5-PPAR (30), pCMX-ER, and vitellogeninA2-ERE-
TKLuc (ER-luc) (31) were described before. The pCMV-Gal
construct was used to control the transfection efficiency.
Transfections—Transfections were preformed either by the
BES-buffered saline method (26) or by JetPei (Polyplus Trans-
fections, Illkirch, France).
Luciferase Activity Measurement—3  105 HEK cells were
seeded in 6-well plates and were transfected with pSuper-
siPARP-2, pSuper-scrPARP-2, pBabe, or pBabe-PARP-2 using
the BES-buffered saline method. Two days later the cells were
once more transfected with the constructs mentioned above.
Cells were transfected 24 h later with 0.6g of pSuper-siPARP-
2/pSuper-scrPARP-2/pBabe/pBabe-PARP-2, 0.4g of-galac-
tosidase expression plasmid, 1 g of pSG-PPAR/pSG-
PPAR/pSG-PPAR2/pCMX-ER expression vector, and 1g
of PPAR-/ER-responsive construct. Six hours after transfec-
tion, cells were scraped, and luciferase activity was determined.
For the determination of PPAR activity, just before transfec-
tion, cells were washed in serum-free DMEMmedium, and the
transfection was carried out in DMEMplus 10% fat-free serum.
As ligandwe used, fenofibrate (50M),monoethylhexyl phthal-
ate (100M), troglitazone (5M), and-estradiol (10M). After
6 h of transfection, cells were washed with phosphate-buffered
saline, scraped, and stored at80 °C. Luciferase assay was car-
TABLE 1
Oligonucleotides used to generate pSuper-siPARP-2 and pSuper-scrPARP-2
The interfering sequences are in bold.
Name Sequence (5-3) Structure
siPARP-2 sense GATCTAAGATGATGCCCAGAGGAACTTTCAAGAGAAGTTCCTCTGGGCATCATCTTTTTTTA BglII/sense/loop/antisense/T(5)/HindIII
siPARP-2 antisense AGCTTAAAAAAAGATGATGCCCAGAGGAACTTCTCTTGAAAGTTCCTCTGGGCATCATCTTA HindIII/T(5)/antisense/loop/sense/BglII
scrPARP-2 sense GATCTTTCGGGGAACAAACGTGCAACTTCAAGAGAGTTGCACGTTTGTTCCCCGAATTTTTA BglII/sense/loop/antisense/T(5)/HindIII
scrPARP-2 antisense AGCTTAAAAATTCGGGGAACAAACGTGCAACTCTCTTGAAGTTGCACGTTTGTTCCCCGAAA HindIII/T(5)/antisense/loop/sense/BglII
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ried out by standard procedures. Luciferase activity was
expressed as luciferase activity/-galactosidase activity.
Nile Red Flow Cytometry—To assess the extent of MEF dif-
ferentiation, cytosolic triglyceride content was assessed by
determining Nile red uptake (modified from Ref. 32) followed
by flow cytometry using a FACSCalibur machine (BD Bio-
sciences). Cells were harvested by adding trypsin/EDTA, and
the detached cells were stained with Nile red (20g/ml, 5min).
Cells were subjected to flow cytometric analysis with 10,000
events collected for each sample; each measurement point was
repeated in 4 parallel replicates. Samples for each cell line were
normalized against the non-differentiated cells of the same line.
The rate of differentiation was expressed as the percentage of
the differentiated cells versus total number of cells.
SDS-PAGE and Western Blotting—Cells were lysed in lysis
buffer (50 mM Tris, 500 mM NaCl, 1 mM EDTA, 1% Nonidet
P-40, 1 mM phenylmethylsulfonyl fluoride, protease inhibitor
mixture, pH 8.0). Proteins were separated by SDS-PAGE and
transferred onto nitrocellulose membranes. For the detection
of PARP-2, a polyclonal rabbit antibody was used 1:2,000,
Alexis, Lausen, Switzerland), and actin was as detected using a
rabbit polyclonal antibody (Sigma, 1:200). The secondary anti-
body was IgG-peroxidase conjugate (Sigma, 1:10,000). Reac-
tions were developed by enhanced chemiluminescence (Amer-
sham Biosciences, Little Chalfont, UK).
Total RNA Preparation, Reverse Transcription, and qPCR—
Total RNA was prepared using TRIzol (Invitrogen) according to
the manufacturer’s instructions. RNA was treated with DNase,
and 2 g of RNA was used for reverse transcription (RT). cDNA
was purified on QIAquick PCR cleanup columns (Qiagen, Valen-
cia,CA). 50dilutedcDNAwasused forquantitativePCR(qPCR)
reactions. The qPCR reactions were preformed using the Light-
Cycler system (Roche Applied Science) and a qPCR Supermix
(Qiagen) with the primers summarized in Table 2.
Chromatin Immunoprecipitation—Chromatin immunopre-
cipitation was performed according to a previous study (33) on
3T3-L1 cells using -PARP-2, -PPAR2 (Alexis), and -ma-
trix metalloproteinase-9 (Santa Cruz Biotechnology, Santa
Cruz, CA) antibodies. We used also a no antibody control. The
chromatin fragments collected upon precipitation with the
above antibodies were amplified using promoter-specific prim-
ers by qPCR. For the analysis of the coding sequence the same
qPCR primer set was used as the one for the quantitation of the
given gene. The respective primers are listed in Tables 2 and 3.
The results were normalized for the signal of the input andwere
expressed as a percentage of the aP2 signal with the PARP-2
antibody.
For the testing of the K19 primer set we used non-confluent
3T3-L1 cells transfected with pCMX-ER. Chromatin immu-
noprecipitation was performed using the -ER (Santa Cruz
Biotechnology), and as controls we used an -MRE11 (Santa
Cruz Biotechnology) and a no antibody control. The chromatin
fragments collected upon precipitationwith the above antibod-
ies were amplified using K19 promoter-specific primers by
qPCR.
Microscopy—Formaldehyde-fixed, paraffin-embedded sec-
tions (7 m) were made from WAT samples and were
stained with hematoxylin and eosine. The same sections
were stained with a biotin-conjugated F4/80 antibody (Sero-
tec, Raleigh, NC, 1:100 dilution), and the bound primary
antibodies were detected using streptavidin-peroxidase
(Vector ABC kit) and diaminobenzidine as chromogenic
substrate. Terminally differentiated MEFs were stained by
Oil red O as described elsewhere.
TABLE 2
qPCR primers
FAS, fatty acid synthase; LPL, liproprotein lipase; HSL, hormone-sensitive lipase.
Name Sequence (5-3) Accession number
Adiponectin F 5-AAG AAG GAC AAG GCC GTT CTC TT-3 (652–674) NM_009605.4
R 5-GCT ATG GGT AGT TGC AGT CAG TT-3 (875–853)
aP2 F 5-TGC CAC AAG GAA AGT GGC AG-3 (132–151) BC054426
R 5-CTT CAC CTT CCT GTC GTC TG-3 (294–275)
CD36 F 5-GAT GTG GAA CCC ATA ACT GGA TTC AC-3 (1378–1403) NM_007643
R 5-GGT CCC AGT CTC AAT TAG CCA CAG TA-3 (1527–1502)
Cyclophylin B F 5-TGG AGA GCA CCA AGA CAG ACA-3 (561–581) M60456
R 5-TGC CGG AGT CGA CAA TGA T-3 (626–608)
FAS F 5-GCT GCG GAA ACT TCA GGA AAT-3 (6612–6632) BC046513
R 5-AGA GAC GTG TCA CTC CTG GAC TT-3 (6695–6673)
LPL F 5-AGG ACC CCT GAA GAC AC-3 (317–333) BC003305
R 5-GGC ACC CAA CTC TCA TA-3 (465–449)
Leptin F 5-GAC ACC AAA ACC CTC AT-3 (147–163) NM_008493
R 5-CAG AGT CTG GTC CAT CT-3 (296–280)
Perilipin F 5-GCT TCT TCC GGC CCA GC-3 (1511–1527) NM_175640
R 5-CTC TTC TTG CGC AGC TGG CT-3 (1580–1561)
PPAR1 F 5-CCA CCA ACT TCG GAA TCA GCT-3 (158–178) NM_011146
R 3-TTT GTG GAT CCG GCA GTT AAG A-3 (591–570)
PPAR2 F 5-ATG GGTG AAA CTC TGG GAG ATT CT-3 (46–69) AY243585
R 5-CTT GGA GCT TCA GGT CAT ATT TGT A-3 (346–322)
HSL F 5-CCT CAT GGC TCA ACT CC-3 (1633/2075–1649/2091) NM_001039507.1/NM_010719.5
R 5-GGT TCT TGA CTA TGG GTG A-3 (2067/2509–2049/2491)
TNF F 5-GCC ACC ACG CTC TTC TG-3 (286–302) NM_013693.2
R 3-GGT GTG GGT GAG GAG CA-3 (627–611)
TABLE 3
Chip primers
Name Sequence Reference
aP2 F 5-CCC AGC AGG AAT CAG GTA GC-3 52
R 5-AGA GGG CGG AGC AGT TCA TC-3
CD36 F 5-TTT GCT GGG ACA GAC CAA TC-3 39
R 5-GCC ATG TTC CCA TCC AAG TA-3
K19 F 5-AAG GGT GGA GGT GTC TTG GT-3 AF237661
R 5-GCT TCT TTA CAC TCC TGC T AAA-3
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Triglyceride Measurement—The triglyceride content of the
MEFs was determined using a commercially available Sigma kit
according to the manufacturer’s instructions.
Statistical Analysis—Significancewas analyzed by Student’s t
test. Error bars represent S.E., unless noted otherwise.
RESULTS
In Vivo Dysfunction of the PPAR/RXR Heterodimer in the
WAT of PARP-2/ Mice—The different fat depots (epididy-
mal,mesenteric, and inguinal) and the interscapular brown adi-
pose tissue-associated WAT were measured in 7-month-old
PARP-2/ mice and their wild-type littermates. A propor-
tional loss of the weight of all adipose tissue depots was
observed in the PARP-2/mice (Fig. 1A).
Histological examination of the PARP-2/ epididymal
WAT showed adipocytes with reduced and irregular size. This
tissue contained diluted capillaries, indicative of inflammation,
which was confirmed by a faint staining with the macrophage-
specific F4/80 antibody in the PARP-2/ (Fig. 1, B and C) and
the macroscopic appearance of theWAT (Fig. 1A). The F4/80-
positive cells were present in the vicinity of the blood vessels.
To identify the molecular changes that contribute to the
decreased fat accumulation and abnormal adipocyte morphol-
ogy, we determined the expression of the PPAR target genes,
TNF, and hormone-sensitive lipase by RT-qPCR in the epi-
didymal WAT.
TNF expression was undetectable in 8 of the 22 mice used
for this study (4 out of 14 PARP-2/ and 4 out of 8 PARP-
2/). In the TNF-positive mice, expression levels were not dif-
ferent, ruling out a major role for inflammation in the adipose
tissue dysfunction in PARP-2/mice. The expression level of
hormone-sensitive lipase, which is responsible for lipolysis, was
also not different between the two genotypes. The expression of
several PPAR target genes, however, was markedly decreased.
These include genes involved in chylomicron and very low den-
sity lipoprotein triglyceride hydrolysis (lipoprotein lipase), free
fatty acid uptake (CD36), de novo fatty acid synthesis, and endo-
crine signaling (leptin and adiponectin) (Fig. 1D). Interestingly,
FIGURE1.AbnormalWAT function inPARP-2/mice.A, weight andmacroscopic viewof different adipose tissuedepots in PARP-2/ andPARP-2/mice
(age of 7 months). In the PARP-2/mice there is a significant reduction of the different fat depots. Error bars represent S.E. *, p 0.05; **, p 0.01. B, the
epididymalWAT stainedwithH&E (100magnification).C, thearrowpoints toward adilated capillary in the PARP-2/ epididymalWAT (100magnification,
H&E). Staining with the F4/80 antibody detects macrophages (marked by #) in the vicinity of the dilated capillaries (*). D, gene expression in epididymal WAT.
*, p 0.05.
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no difference was detected in PPAR1 and PPAR2 mRNA lev-
els between the different genotypes.
MEF Differentiation Is Affected by PARP-2 Ablation—We
next aimed to determine whether MEFs differentiation toward
adipocyteswas affected by the PARP-2 deletion.Differentiation
of PAPR-2/ MEFs into adipocytes was decreased as judged
by Oil red O staining, determination of lipid content, and Nile
red staining followed by fluorescence-activated cell sorting
analysis (Fig. 2A).
The expression of genes involved in adipocyte differentiation
and function such as PPAR1 and PPAR2 were decreased in the
PARP-2/ MEFs (34). Because the PPAR transcripts are pri-
marily present in the differentiated cells, these data confirm that
PARP-2/ cells differentiate less into adipocytes. The expression
of PPAR target genes, such as lipoprotein lipase, fatty acid syn-
thase, leptin, adiponectin, andadipocyte fattyacid-bindingprotein
2 (aP2), were decreased in parallel (Fig. 2B).
PARP-2 Expression Modulates Transactivation of PPARs—
To measure whether changes in PARP-2 expression affect
PPAR transactivation, we usedHEK 293 cells transfectedwith a
PPAR2 expression vector and a PPAR-responsive luciferase
construct. In these experiments we modulated the expression
of PARP-2 expression by overexpression and siRNA depletion.
For the siRNA depletion of PARP-2 we used the pSuper-
siPARP-2 construct, whereas for PARP-2 overexpression we
used the pBabe-PARP-2. The pSuper-scrPARP-2 and the
empty pBabe vector served as the respective controls. PARP-2
levels were assessed by Western blotting using a PARP-2-spe-
cific antibody. For both constructs, the cells were transfected
twice, on day 0 and on day 2. On day 3, the specific siRNA
decreased PARP-2 protein levels significantly, whereas the
scrambled PARP-2 siRNA did not alter the PARP-2 levels. A
strong increase in PARP-2 protein was observed on day 3 of the
overexpression experiment (Fig. 3).
PARP-2 depletion diminished the basal PPAR activity and
abrogated receptor activation by its synthetic ligand, troglita-
zone. Conversely, PARP-2 overexpression induced by 3-fold
the basal PPAR activity, although it does not significantly
change the ligand-dependent activation by troglitazone (Fig.
4A). To verify whether this effect of PARP-2 was specific for
PPAR, we performed similar experiments for the related
nuclear receptors PPAR (NR1C1) and PPAR (NR1C2), and
FIGURE 2.Effect of PARP-2onMEFdifferentiation into adipocytes.A, MEFswere differentiated into adipocytes and stainedwithOil redO.On the terminally
differentiatedMEFs, Nile red fluorescence-activated cell sorting analysis and lipidmeasurements were performed. The left histogram shows the percentage of
differentiation as measured with Nile red, and the right histogram shows the accumulation of lipids in the culture. *, p 0.05; **, p 0.01. B, expression of
selected marker genes of adipocyte differentiation as measured by RT-qPCR on MEF cDNA samples (*, p 0.05; **, p 0.01).
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the unrelated estrogen receptor  (ER, NR3A2). Interestingly,
siRNA depletion of PARP-2 increased the basal activity of both
PPAR and - (Fig. 4,B andC). PARP-2 overexpression did not
affect PPAR but increased PPAR activity. The activation of
PPAR and -with fenofibrate andmonoethylhexyl phthalate,
respectively, was not modified by the modulation of PARP-2
expression. In addition, neither PARP-2 depletion, nor PARP-2
overexpression had an effect on the basal or ligand-induced
activity of ER (Fig. 4D). Combined these results indicate spec-
ificity of the PARP-2-dependent effect on PPAR.
PARP-2 Is the Member of the RXR/PPAR Transcription
Complex—To demonstrate an interaction between PPAR and
PARP-2 we used ChIP assays. To precipitate chromatin from
undifferentiated 3T3-L1 cells we used antibodies against
PARP-2 andPPAR2. An anti-matrixmetalloproteinase-9 anti-
body and a sample without antibody served as negative con-
trols.Weused qPCR to amplify the promoters of the aP2 (6) and
CD36 (35) as promoters driven by PPAR, and keratin-19
(K19), as a non-related, ER-regulated promoter (36). PARP-2
and PPAR gave a strong signal on PPAR-regulated promot-
ers. These signals were significantly higher compared with the
signal from the K19 promoter (Fig. 5A). We also performed
qPCR reactions to cover the coding sequences of aP2 using the
chromatin fragments obtained in the ChIP experiments. The
signal of PARP-2 and PPAR coding sequences in the immu-
noprecipitates was strongly decreased compared with the sig-
nal of the corresponding promoter. Apparently, both PARP-2
and PPAR are present on the PPAR-driven promoters but
not in the coding sequence (Fig. 5B). In addition, our results
suggest that PARP-2 possesses specificity toward the PPAR-
driven promoters, because the signal from ER-driven K19
promoter was significantly lower than that from PPAR-driven
promoters.
Despite the huge difference in the signal of the specific pro-
moters and the nonspecific regions (K19 promoter, coding
sequence) we observed some background signal from the non-
specific region. It is likely that this represents the real presence
of PARP-2 in these regions, which is probably linked to the
formaldehyde-induced DNA damage.
To provide proof that the interaction of ER with the K19
promoter is basically detectablewe complemented 3T3-L1 cells
with ER, andwe performedChIP probingwith theK19 primer
set. To precipitate chromatin from ER-complemented
3T3-L1 cells we used an antibody against ER, an anti-MRE11
antibody and a sample with no antibody served as negative con-
trols. The precipitate of the ER-specific antibody gave signif-
icantly higher signal then the non-
specific MRE11 (2.7-fold increase)
as well as with the non-antibody
control (6.1-fold increase) proving
that the K19 primer pair is capable
of detecting the K19 promoter if
present in the precipitate (Fig. 5C).
DISCUSSION
PPAR plays an important role in
adipose tissue differentiation and
function. In PARP-2 knock-out
mice we have identified a defect of adipose tissue function and
a decrease of adipocyte differentiation. In vivo, the adipose tis-
sue depots had smaller weight and histologically showed an
adipodegenerative phenotype.
We have detected a mild inflammation in the WAT of the
PARP-2/ mice. The capillaries were dilated, and we have
detected F4/80-positive cells in the vicinity of the capillaries
suggesting the presence of macrophages. The areas more
distant from the capillaries are devoid of staining. Similar
coloration was not observed in the WAT of the wild-type
mice. Activated macrophages and adipocytes may secrete
pro-inflammatory cytokines, such as TNF that may induce
adipocyte cell death (37). Because TNF expression was not
detectable in many mice and, if it was detected, its expression
was not significantly increased by the absence of PARP-2, it
is less likely that inflammation is a leading cause of the adi-
podegeneration in the PARP-2/ mice. It is also unlikely
that increased lipolysis may contribute to the phenotype in
the PARP-2/ mice, because there was no difference in the
expression of hormone-sensitive lipase between the wild-type
and PARP-2/mice.
We did observe decreased expression ofmultiple PPAR tar-
get genes involved in adipocyte function. Expression of both
PPAR isoforms was normal, suggesting effects on PPAR/
RXR transactivation. In vitro, the differentiation of the PARP-
2/ MEFs into adipocytes was delayed when compared with
the differentiation of wild-type MEFs. At the end of the differ-
entiation the expression of both PPAR1 and PPAR2 was
decreased in the PARP-2/ cells indicating the lack of differ-
entiation. Similarly, the expression of the PPAR target genes
was decreased.
In transfection assays, the ablation of PARP-2 results in the
diminution, whereas PARP-2 overexpression raises transacti-
vation by PPAR. The effect of PARP-2 seems specific for
PPAR, because opposite or no effects were observed for the
related PPAR and PPAR, and the non-related ER.
PARP-2 achieves these activities, because it is part of the
PPAR/RXR transcription complex as shown by ChIP assays,
suggesting that PARP-2 could act as a PPAR/RXR receptor
cofactor.
Both members of the PPAR/RXR nuclear receptor dimer
might be the effector behind the phenotype of the PARP-2/
mice. If PARP-2 would directly influence RXR, all PPAR iso-
forms should respond the same way to the modulation of
PARP-2 expression. PPAR was differentially regulated when
compared with PPAR and -, suggesting that PARP-2 acts on
FIGURE 3. Characterization of the pSuper-scrPARP-2 and the pSuper-siPARP-2 constructs. 3  107 HEK
cells were plated in Petri dishes and were BES-buffered saline transfected on day 0 and on day 2. Cells were
scraped from day 2 daily. These samples were analyzed by Western blotting. PARP-2 was depleted by the
pSuper-siPARP-2 construct, butwas unmodified by the pSuper-scrPARP-2 construct. Whereas the transfection
with pBabe-PARP-2 resulted on day 3 and day 4 in a robust induction of PARP-2 expression, the transfection
with pBabe alone did not modify PARP-2 expression.
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PPAR. Our report comprises in vitro data and gives first time
in vivo evidence that PARP-2 may be considered a cofactor of
nuclear receptor transcription.
PARP-2 is a multidomain protein with multiple functions.
These functions comprise DNA repair (reviewed in Ref. 15),
spermatogenesis (16, 17), T-cell development (38), inflamma-
tion, and oxidative injury (18–20). Most of these functions are
accomplished through protein-pro-
tein interactions. The N terminus,
with the following domain E are
apparently important protein-pro-
tein interaction domains, serving as
an interaction platform for TRF-2
(21), B23 (22), PARP-1, XRCC1, and
DNA polymerase  (23), and TTF1
(25). PARP-2 also homodimerizes
with itself through its domain E
(23).
PARP-1 has been described as a
cofactor for numerous transcription
factors (reviewed in 40 and 25),
including for some members of the
nuclear receptor family, such as the
progesterone receptor (41), RXR
(42, 43), androgen receptor (44),
and the thyroid receptor (42). A
recent study, based on in vitro
results, suggested that PARP-2 acts
as a cofactor of a homeodomain-
containing transcription factor,
TTF1, which belongs to the Nkx-2
family. Binding of PARP-2 through
its E domain to the C terminus of
TTF1 regulates the expression of
the surfactant protein-B in lung
epithelial cells. TTF1-mediated
transcription encompasses similar
mechanisms, including chromatin
modification, and involves some
of the same cofactors such as the
steroid receptor coactivators as
described for PPAR-coupled
transcription. This suggests that
similar molecular mechanisms
exist both in the case of PPAR-
and TTF1-mediated transcription
(25). Our results hence confirm
the observation of Maeda and col-
leagues (25), that PARP-2 is a
cofactor of some transcription fac-
tors, and extend these conclusions
by showing that PARP-2 is
involved in nuclear receptor-me-
diated transcriptional control in
vivo. Recent evidence has sug-
gested that the interaction
between PARP-1 and the pro-
moter of target gene could be
mediated via double strand breaks, which are produced by
activation of a nuclear receptor followed by the unwinding of
DNA by topoisomerase II (45). Our results do provide evi-
dence that interaction with DNA is important for the inter-
action between PPAR and PARP-2. ChIP assays that
depend on DNA binding show strong interaction. In con-
trast, immunoprecipitation experiments performed on cell
FIGURE 4. Effect of PARP-2 expression levels on PPAR2 transactivation. Effect of PARP-2 depletion and
overexpression on the basal activity and receptor activation of PPAR (A), PPAR (B), PPAR (C), and ER (D)
receptors. Error bars representS.D. ### and ***, p 0.001; **, p 0.01; #, p 0.05.
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extracts showed only a weak interaction between PARP-2
and PPAR (data not shown), which was abrogated by low
concentrations of Nonidet P-40 (0.1%). Furthermore, like
in the case for PARP-1, the N terminus of PARP-2, compris-
ing its DNA-binding domain, seems also to play the most
important role in the interaction with PPAR. Consistent
with this observation a nuclear receptor-binding consensus
sequence (113LIQLL117) was present in the E domain of
PARP-2.
Concerning the mode of action of PARP-2, it is possible
that not only the physical presence but also the activity of
PARP-2 is necessary for the nuclear receptor function. Poly-
(ADP-ribosyl)ation is reported to increase throughout the
differentiation process of 3T3-L1 cells (46). Interestingly,
this poly(ADP-ribosyl)ation activity is not completely inhib-
ited by PARP-1 depletion (47), suggesting the involvement of
other member(s) of the PARP family, such as PARP-2.
Indeed both PARP-1 and PARP-2 are reported to poly(ADP-
ribosyl)ate histones (13). Similarly to histone acetylation,
poly(ADP-ribosyl)ation of the high mobility group of pro-
teins and histones loosens chromatin structure enabling
transcription initiation (48). Consistent with this line of
thinking, there is molecular and in vivo evidence that the
enzymatic activity of PARP-1 is necessary for efficient gene
transcription, and inhibition of PARP activity impairs the
transcription of a number of different genes, including dif-
ferent chemokines and inflammation-related genes (e.g.
iNOS, TNF, ICAM-1, IL-8, MIP-1, and IL-12) (40, 49, 50).
PARP-2 specifically occupies the promoter of PPAR target
genes, because it bound efficiently to the regulatory sequence,
whereas binding to the corresponding coding sequences was
strongly decreased. Despite this rather specific binding, we
observed a background signal rising most likely from non-cod-
ing regions or from non-PPAR-dependent promoters, such as
that of the K19 gene, which is under the control of ER. When
comparing the specific to the abovementioned nonspecific sig-
nal, it is at least 10- to 100-fold increased, which can be consid-
ered as a significant difference. It is likely that the nonspecific
presence of PARP-2 on the K19 promoter and in the non-cod-
ing regions is explained by the fact that PARP-2 binds to the
DNA-damage sites created by the formaldehyde treatment dur-
ing the cross-linking of the cells. The cross-linking-related
DNA damage is present throughout the entire genome, equally
affecting coding regions and promoters, thus theoretically pro-
viding a background signal throughout the genome.
The present study indicates that PARP-2 modulates the
activity of PPAR/RXR nuclear receptor complex, a key tran-
scription factor involved in the pathogenesis of several impor-
tant diseases such as obesity, insulin resistance, type II diabetes
atherosclerosis, and lipodystrophy. Because many of these dis-
eases affect a large part of the population and have high costs to
society, our data, linking the activation of PPAR and PARP-2,
show it is possible to modulate PPAR activity via PARP-2. It is
therefore tempting to speculate that the various PARP inhibi-
tors that are currently being developed and tested in clinical
trials (51) could also be useful in the metabolic disease arena.
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